Home/Pipeline/Platform Development (EVE16™ + targeted LNPs)

Platform Development (EVE16™ + targeted LNPs)

Undisclosed (Likely Oncology/Immunology)

Pre-clinicalActive

Key Facts

Indication
Undisclosed (Likely Oncology/Immunology)
Phase
Pre-clinical
Status
Active
Company

About InnDura Therapeutics

InnDura Therapeutics is an early-stage biotech focused on next-generation cell and gene therapies using in vivo mRNA delivery. Its core technology integrates targeted LNPs with the proprietary EVE16™ platform to reprogram immune cells directly within the patient's body, aiming for more effective and accessible immunotherapies. The company is pre-clinical and pre-revenue, operating as a private entity. Its location in Cambridge provides access to top-tier talent, capital, and research collaborators, positioning it to advance its platform toward clinical development.

View full company profile

Therapeutic Areas

Other Undisclosed (Likely Oncology/Immunology) Drugs

DrugCompanyPhase
Undisclosed BLA-Stage AssetXOMABLA Submission